Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib

BACKGROUND: The ‘Prediction Of Survival in Advanced Sorafenib‐treated HCC’ (PROSASH) model addressed the heterogeneous survival of patients with hepatocellular carcinoma (HCC) treated with sorafenib in clinical trials but requires validation in daily clinical practice. This study aimed to validate,...

Descripción completa

Detalles Bibliográficos
Autores principales: Labeur, Tim A., Berhane, Sarah, Edeline, Julien, Blanc, Jean‐Frederic, Bettinger, Dominik, Meyer, Tim, Van Vugt, Jeroen L. A., Ten Cate, David W. G., De Man, Robert A., Eskens, Ferry A. L. M., Cucchetti, Alessandro, Bonnett, Laura J., Van Delden, Otto M., Klümpen, Heinz‐Josef, Takkenberg, R. Bart, Johnson, Philip J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Liver Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973249/
https://www.ncbi.nlm.nih.gov/pubmed/31579990
http://dx.doi.org/10.1111/liv.14270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973249/
https://www.ncbi.nlm.nih.gov/pubmed/31579990
http://dx.doi.org/10.1111/liv.14270

Ejemplares similares